Medicare locks in high prices for wound products, bars clinical review

What it does

This bill creates a new Medicare payment category for skin substitute products (cellular or tissue-based wound treatments) from 2027–2030, setting a fixed reimbursement rate of $457 per square centimeter and requiring products to be domestically sourced, harvested, and manufactured. It imposes strict oversight on providers—including prepayment review, prior authorization, and certification requirements—and bars Medicare from denying coverage based solely on clinical evidence during 2027. The bill benefits wound-care manufacturers and certified providers who meet domestic-sourcing rules, while imposing compliance costs and payment floors on the industry.

Why we flagged it

The bill's operative mechanism is a fixed reimbursement rate and minimum provider cost floor for a specific product category, combined with a domestic-sourcing requirement that restricts supply and a coverage guarantee that insulates the category from clinical-evidence review during 2027. This is a hybrid of price-setting and supply-chain protectionism.

What the text implies

• The $457/sq cm payment rate and $342.75/sq cm cost floor are set by statute without reference to actual production costs, clinical outcomes, or competitive pricing—locking in margins for 4 years and creating a de facto price floor that may inflate Medicare spending.
• The domestic-sourcing requirement (all harvesting, processing, manufacturing in US; all human material from US citizens/permanent residents) may exclude lower-cost international products and reduce supply diversity, potentially raising prices for patients and Medicare.

The full analysis lists 5 implications of this text.

Who stands to gain

skin substitute product manufacturers (domestic only); certified wound-care providers and specialists; wound-care clinics and hospitals with certified staff